Malignant (Pleural) Mesothelioma Clinical Trial
Official title:
Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma
Earlier the investigators determined the safety and feasibility of tumor lysate-pulsed dendritic cells as therapeutic adjuvants in mesothelioma patients. Because pre-clinical data in mice had shown that better results were obtained when regulatory T cells were depleted using low-dosis of cyclophosphamide, ten patients who responded on chemotherapy are selected for DC-treatment in combination with Endoxan.
Currently there is no satisfactory low-toxicity treatment for patients with mesothelioma
(MM). Based on studies in other types of cancer in humans where beneficial effects were
obtained, and based on our pre-clinical data in a mouse model for MM, led to the
introduction of DC-immunotherapy for human MM in 2005. A beneficial effect of immunotherapy
in MM patients without major side effects was found, however, research has shown that DC
immunotherapy might be further improved. The objectives of the here proposed phase study
are:
- To define the safety and toxicity of low dose CTX in combination with MesoCancerVac in
patients with MM.
- To determine if vaccination with low dose CTX in combination with MesoCancerVac results
in a detectable immune response by skin DTH reactions on MM crude antigen and KLH and
by in vitro laboratory analysis.
- To observe and document anti-cancer activity by laboratory evaluation (e.g. decrease in
Tregs, increase in CTLs using 51Cr release and IFN-gamma ELISPOT)
- To observe and document anti-cancer activity by clinical evaluation (e.g. CT scan)
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment